<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Advances in Medical and Biomedical Research</title>
<title_fa>Journal of Advances in Medical and Biomedical Research</title_fa>
<short_title>J Adv Med Biomed Res</short_title>
<subject>Medical Sciences</subject>
<web_url>http://journal.zums.ac.ir</web_url>
<journal_hbi_system_id>52</journal_hbi_system_id>
<journal_hbi_system_user>journal52</journal_hbi_system_user>
<journal_id_issn>1606-9366</journal_id_issn>
<journal_id_issn_online>2676-6264</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.30699/jambr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1405</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2026</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<volume>2026</volume>
<number>Articles In Press</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Association of ESR1 rs2234693 Polymorphism with Letrozole-Related Biomarker and Tolerability Outcomes in Iraqi Postmenopausal Women with Estrogen Receptor-Positive Breast Cancer</title>
	<subject_fa>Life Science</subject_fa>
	<subject>Life Science</subject>
	<content_type_fa>مقاله پژوهشی</content_type_fa>
	<content_type>Original Research Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:inter-ideograph&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;Methods&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;: This exploratory cross-sectional pharmacogenetic study enrolled 100 Iraqi postmenopausal women with estrogen receptor-positive breast cancer who had received letrozole 2.5 mg once daily for at least three months. ESR1 rs2234693 was selected as the primary variant for genotype&amp;ndash;phenotype analysis, whereas rs9340799 was additionally genotyped for descriptive purposes. Genotyping was performed using allele-specific PCR/ARMS-PCR and visualized and interpreted by agarose gel electrophoresis. The assessed biomarkers included estradiol, CA15-3, calcium, osteocalcin, and bone-specific alkaline phosphatase. Letrozole-related symptoms were assessed clinically. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:inter-ideograph&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;&lt;b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;Results&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;: ESR1 rs2234693 genotype frequencies were 29% for TT, 28% for TC, and 43% for CC, with corresponding T and C allele frequencies of 43% and 57%, respectively. In contrast, ESR1 rs9340799 was monomorphic, as all participants carried the AA genotype; therefore, subsequent association analyses were limited to rs2234693. Under the dominant genetic model for rs2234693, TC/CC carriers showed a nominal exploratory association with higher CA15-3 levels compared with TT carriers (P = 0.036), whereas no significant differences were observed in estradiol or bone-related biomarkers. In exploratory logistic regression, TC/CC carriers showed lower odds of hair loss than TT carriers (OR = 0.39, 95% CI: 0.16&amp;ndash;0.97; P = 0.042).&lt;/span&gt;&lt;/span&gt;&lt;span dir=&quot;RTL&quot; lang=&quot;AR-SA&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;line-height:115%&quot;&gt;&lt;span style=&quot;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;Conclusion&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;: ESR1 rs2234693 showed appreciable variability in this Iraqi cohort and produced limited nominal exploratory associations with CA15-3 and hair loss.&lt;/span&gt;&lt;/span&gt; &lt;span style=&quot;font-size:8.0pt&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;These findings require prospective validation before clinical implementation.&lt;/span&gt;&lt;/span&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>ESR1, Letrozole, Breast Cancer, Pharmacogenetics, rs2234693, rs9340799, Iraqi Patients</keyword>
	<start_page>50</start_page>
	<end_page>50</end_page>
	<web_url>http://journal.zums.ac.ir/browse.php?a_code=A-10-7570-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>Sajad Hassan Sabir</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>SajadHassanSabir@gmail.com</email>
	<code>5200319475328460090462</code>
	<orcid>5200319475328460090462</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>Zahraa Abd Al-Kareem</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ZahraaAbdAl-Kareem@gmail.com</email>
	<code>5200319475328460090463</code>
	<orcid>5200319475328460090463</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>Shaima Jabbar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>shaymaa.a@uokerbala.edu.iq</email>
	<code>5200319475328460090464</code>
	<orcid>5200319475328460090464</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>Ali Abd Al-Rasool Al-Mukhtar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>AliAbdAl-RasoolAl-Mukhtar@gmail.com</email>
	<code>5200319475328460090465</code>
	<orcid>5200319475328460090465</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Ali Abd Al-Rasool Al-Mukhtar Department of Oncology and Radiotherapy, Al-Imam Al-Hassan Al-Mujtaba Teaching Hospital, Kerbala Health Directorate, Karbala, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
